UBS Group »

Engene Therapeutics shares owned by UBS Group

Quarter-by-quarter ownership of Engene Therapeutics (ENGN) shares owned by UBS Group from 13F filings

Historical chart of UBS Group investment in Engene Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Engene Therapeutics held by UBS Group consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Engene Therapeutics by UBS Group

Quarter filed Position value Share count Share price at filing
2026-06-30 $881k 509k 1.73

More positions owned by UBS Group

State Str Spdr S&p 500 Etf T Tr Unit (SPY)
NVIDIA Corporation (NVDA)
Apple (AAPL)
Microsoft Corporation (MSFT)
Invesco Qqq Tr Unit Ser 1 (QQQ)
Micron Technology (MU)
Eli Lilly & Co. (LLY)
Amazon (AMZN)
Alphabet Cap Stk Cl A (GOOGL)
Broadcom (AVGO)
JPMorgan Chase & Co. (JPM)
Advanced Micro Devices (AMD)
Alphabet Cap Stk Cl C (GOOG)
Meta Platforms Cl A (META)
Ishares Tr Core Msci Eafe (IEFA)

View all positions for UBS Group

Top funds holding Engene Therapeutics

BML Capital Management
Siren
Perceptive Advisors
Ameriprise Financial
Nextech Invest
ADAR1 Capital Management
Vestal Point Capital
Acorn Capital Advisors
Peapod Lane Capital
Balyasny Asset Management
Millennium Management
Renaissance Technologies
Citadel Advisors
Affinity Asset Advisors
UBS Group

View all funds holding Engene Therapeutics